Yes, this recommendation is a bit late, however, the research is quite positive, and the upside is still on the table. August will bring a likely approval of SD-101, in combination with Keytruda. The potential 500M annual market opportunity would significantly change their revenue outlook, athough they might need some extra money to make that a reality, the key is the drugs approval. This is a bit of a fence swinging attempt, so the position is small, but still a larger % risk than normal. Big money has been coming in lately, so the chart looks primed. Sorry I didn't see this at 7. Best!
Not the sax player...I've been investing and trading for a decade. All my first hand experience and academic study of the markets and human behavior has taught me that your only friend with regard to caring for your money is your own prudent judgement. I'm happy though, to give quick assessments of any issue technically or fundamentally, and do the deeper research that could help you make up your own mind.
Anyone that tells you that they can predict the stock market with certainty is either deluded or selling you something. We can't predict where stock prices will go, but it is still possible to make money by investing with a strategy, even if you're wrong more often than you are right. Sticking with winning trades that work over the long haul and being humble enough to cut your losses early is the key to success. I believe in using realistic back-tested strategies that aren't over-fit.